Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | SI | P14410 | 2/20 | 0.51 |
| ▸ | MGAM2 | Q2M2H8 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | EIF4E | P06730 | 7/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | BACE1 | P56817 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL995671 | 0.81 | TSHR (0.50) | ALDH1A1MAPTMAPK1SMN1; SMN2EIF4E | |
| SCHEMBL9832354 | 0.81 | MGAM (0.59) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL6415841 | 0.79 | EIF4E (0.43) | ALDH1A1MAPTMAPK1SMN1; SMN2EIF4E | |
| SCHEMBL1208143 | 0.78 | EIF4E (0.70) | ALDH1A1EIF4ETDP1 | |
| SCHEMBL6416281 | 0.78 | MGAM (0.46) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL6416284 | 0.78 | MGAM (0.46) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL6185761 | 0.77 | ACHE (0.56) | EIF4E | |
| SCHEMBL6367549 | 0.76 | HDAC3 (0.49) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL3711601 | 0.76 | ALDH1A1 (0.41) | GAAALDH1A1MAPTMAPK1SMN1; SMN2 | |
| SCHEMBL996621 | 0.76 | GAA (0.49) | GAAALDH1A1MAPTMAPK1EIF4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143277-B2 | Method of using compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity | THERAVANCE, INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-20090239904-A1 | COMPOUNDS HAVING BETA2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY | THERAVANCE, INC. (US) | 2009-09-24 | — | — | US | disclosed |
| US-7569586-B2 | Compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity | THERAVANCE, INC. (US) | 2009-08-04 | — | — | US | disclosed |
| EP-1833822-A2 | COMPOUNDS HAVING BETA2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY | Theravance, Inc. (US) | 2007-09-19 | — | — | EP | disclosed |
| WO-2006023460-A2 | COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY | THERAVANCE, INC. (US) | 2006-03-02 | — | — | WO | disclosed |
| US-20060035933-A1 | Compounds having beta adrenergic receptor agonist and muscarinic receptor antagonist activity | THERAVANCE BIOPHARMA R&D IP, LLC | 2006-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035933-A1 | Compounds having beta adrenergic receptor agonist and muscarinic receptor antagonist activity | ADRA2B, ADRB1, ADRA1B | MGAM 2813/4885GAA 4163/4885SI 4659/4885 |
| US-20090239904-A1 | COMPOUNDS HAVING BETA2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY | ADRA2B, ADRB2, ADRB1 | MGAM 2672/4885GAA 4091/4885SI 4587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.